Similar articles for PMID: 33990403

Year	Number of Results
2015	2
2016	3
2017	4
2018	9
2019	13
2020	12
2021	19
2022	21
2023	25
2024	3

1

PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.

Barbato F, Fendler WP, Rauscher I, Herrmann K, Wetter A, Ferdinandus J, Seifert R, Nader M, Rahbar K, Hadaschik B, Eiber M, Gafita A, Weber M. Barbato F, et al. J Nucl Med. 2021 May 14;62(12):1747-50. doi: 10.2967/jnumed.121.262120. Online ahead of print. J Nucl Med. 2021. PMID: 33990403 Free PMC article.

2

Survival of patients with lymph node versus bone versus visceral metastases according to CHAARTED/LATITUDE criteria in the era of intensified combination therapies for metastatic hormone-sensitive prostate cancer.

Wenzel M, Wagner N, Hoeh B, Siech C, Koll F, Cano Garcia C, Ahrens M, Tilki D, Steuber T, Graefen M, Banek S, Chun FKH, Mandel P. Wenzel M, et al. Prostate. 2024 Oct;84(14):1320-1328. doi: 10.1002/pros.24767. Epub 2024 Jul 10. Prostate. 2024. PMID: 38987984

3

Impact of non-regional lymph node metastases accurately revealed on ¹⁸F-PSMA-1007 PET/CT in the clinical management of metastatic hormone-sensitive prostate cancer.

Jiang Z, Fan J, Gan C, Dong X, Gao G, Wang Z, He D, Li L, Duan X, Wu K. Jiang Z, et al. EJNMMI Res. 2023 Jul 6;13(1):64. doi: 10.1186/s13550-023-01009-x. EJNMMI Res. 2023. PMID: 37410264 Free PMC article.

4

A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-naïve prostate cancer.

Miyoshi Y, Yasui M, Yoneyama S, Kawahara T, Nakagami Y, Ohno Y, Iizuka J, Tanabe K, Hashimoto Y, Tsumura H, Tabata KI, Iwamura M, Yano A, Kawakami S, Uemura H. Miyoshi Y, et al. BJUI Compass. 2020 Sep 18;2(2):105-114. doi: 10.1002/bco2.46. eCollection 2021 Mar. BJUI Compass. 2020. PMID: 35474890 Free PMC article.

5

Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial.

Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Visschere P, Ost P, Verbeke S, Villeirs G, De Man K, Rottey S, Decaestecker K, Lumen N. Buelens S, et al. Urol Oncol. 2018 Apr;36(4):158.e13-158.e20. doi: 10.1016/j.urolonc.2017.12.009. Epub 2018 Jan 12. Urol Oncol. 2018. PMID: 29336978 Clinical Trial.

6

A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and ¹⁸F-PSMA-PET/CT.

Bodar YJL, Luining WI, Keizer B, Meijer D, Vellekoop A, Schaaf M, Hendrikse NH, Van Moorselaar RJA, Oprea-Lager DE, Vis AN. Bodar YJL, et al. Urol Oncol. 2023 Apr;41(4):205.e17-205.e24. doi: 10.1016/j.urolonc.2022.12.006. Epub 2022 Dec 30. Urol Oncol. 2023. PMID: 36588019 Free article.

7

Comparison of ⁶⁸ Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer.

Walacides D, Meier A, Knöchelmann AC, Meinecke D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, von Klot CAJ, Christiansen H, Henkenberens C. Walacides D, et al. Strahlenther Onkol. 2019 May;195(5):420-429. doi: 10.1007/s00066-018-1417-9. Epub 2019 Jan 4. Strahlenther Onkol. 2019. PMID: 30610354 English.

8

⁶⁸Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients.

Liu C, Liu T, Zhang N, Liu Y, Li N, Du P, Yang Y, Liu M, Gong K, Yang X, Zhu H, Yan K, Yang Z. Liu C, et al. Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1852-1861. doi: 10.1007/s00259-018-4037-9. Epub 2018 May 2. Eur J Nucl Med Mol Imaging. 2018. PMID: 29717333

9

A Multicenter Prospective Clinical Trial of ⁶⁸Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.

McCarthy M, Francis R, Tang C, Watts J, Campbell A. McCarthy M, et al. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):801-808. doi: 10.1016/j.ijrobp.2019.03.014. Epub 2019 Mar 16. Int J Radiat Oncol Biol Phys. 2019. PMID: 30890448 Clinical Trial.

10

Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach.

Hartrampf PE, Krebs M, Peter L, Heinrich M, Ruffing J, Kalogirou C, Weinke M, Brumberg J, Kübler H, Buck AK, Werner RA, Seitz AK. Hartrampf PE, et al. Biology (Basel). 2022 Apr 26;11(5):660. doi: 10.3390/biology11050660. Biology (Basel). 2022. PMID: 35625388 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 33990403

91 results

Results by year